The involvement of the stem cell marker CD133 protein in the maintenance of melanoma stemness properties and drug resistance is mediated by its C-terminal domain, which contains tyrosine binding sites located on tyrosine 828 (Tyr828) and tyrosine 852 (Tyr852) residues [74,176]. Here, PROM1 is linked to melanoma.